Psychedelic Therapy Regulation: Australia, Brazil, USA Compared

Australia’s Structured Rescheduling: MDMA and Psilocybin for Psychiatric Use

Australia is the first country to formally reschedule 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin for supervised psychiatric use, establishing a regulated pathway for psychedelic-assisted therapy. On July 1, 2023, the Therapeutic Goods Administration (TGA) reclassified these substances from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines) for use in treatment-resistant depression and post-traumatic stress disorder (PTSD) under the supervision of authorized psychiatrists. This regulatory shift requires practitioners to obtain TGA approval and adhere to strict protocols, including patient selection, informed consent, and ongoing monitoring (TGA announcement).

The Australian model is unique in its national scope and explicit clinical governance, setting a precedent for structured access while maintaining safeguards. However, the system’s complexity—requiring psychiatrist oversight, limited indications, and ongoing data collection—raises questions about scalability and equitable access, particularly in rural or underserved regions.

Brazil: Religious Exemption Amid Regulatory Gaps

Brazil’s approach to psychedelic regulation is characterized by limited legal carve-outs, primarily permitting the use of ayahuasca (a brew containing N,N-dimethyltryptamine, or DMT) within religious ceremonies. The National Health Surveillance Agency (ANVISA) does not currently provide a clinical regulatory framework for professional psychedelic-assisted therapy. Instead, Resolution RDC No. 211/2018 recognizes the religious use of ayahuasca, reflecting Brazil’s constitutional protections for indigenous and Afro-Brazilian traditions (ANVISA).

This context creates a regulatory vacuum for clinical or therapeutic use outside religious contexts. While the religious exemption supports cultural preservation, it leaves patients and clinicians without clear legal pathways for medical use, and raises unresolved questions about the boundaries between spiritual and therapeutic practices. Notably, some local initiatives have attempted to bridge this gap, but lack national legal backing, resulting in inconsistent access and oversight.

United States: Fragmented and Restrictive Landscape

The United States maintains a fragmented and predominantly restrictive regulatory environment for psychedelics, with most substances—including psilocybin, MDMA, and LSD—classified as Schedule I under the Controlled Substances Act (CSA). This federal status denotes high abuse potential and no accepted medical use, limiting access to research settings and special programs. However, state-level reforms have introduced localized exceptions: Oregon’s Measure 109 (2020) established a psilocybin services program, and Colorado’s Proposition 122 (2022) decriminalized certain natural psychedelics for supervised use. These state initiatives operate in legal tension with federal law, creating uncertainty for practitioners and participants (CSA Schedule I).

At the federal level, the Food and Drug Administration (FDA) has granted “breakthrough therapy” status to psilocybin and MDMA for specific psychiatric indications, accelerating clinical trials but not yet translating to approved therapeutic use (FDA announcement). This patchwork results in limited, research-based access and a lack of unified clinical standards, complicating efforts to ensure patient safety and consistent oversight.

Cross-Jurisdictional Challenges: Safety, Access, and Ethics

All three countries face persistent challenges in ensuring patient safety, equitable access, and robust ethical oversight for psychedelic-assisted therapy. Regulatory maturity is shaped by cultural acceptance, healthcare infrastructure, and political priorities. In Australia, the psychiatrist-led model aims to mitigate risks but may restrict access for marginalized populations. In Brazil, the absence of a clinical framework leaves patients reliant on religious exemptions or unregulated services, raising concerns about quality and consent. The U.S. system’s fragmentation exposes patients and providers to legal ambiguity and inconsistent standards.

• Patient Safety: Adequate screening, informed consent, and adverse event monitoring remain inconsistent, particularly outside formal research settings.
• Access and Equity: High barriers to entry in Australia, legal uncertainty in the U.S., and lack of clinical options in Brazil limit equitable access to care.
• Ethical Oversight: Varying degrees of professional training, cultural sensitivity, and protection of indigenous rights complicate ethical governance.

A non-obvious risk is the potential for regulatory “leapfrogging,” where rapid policy changes outpace the development of clinical infrastructure and practitioner training, inadvertently increasing the risk of harm or inequity—an issue already observed in some Australian pilot sites.

Implications and Future Directions for Global Policy

Comparative analysis of Australia, Brazil, and the USA demonstrates that regulatory frameworks for psychedelic therapy are deeply influenced by cultural traditions, healthcare systems, and national policy agendas. The Australian model offers a template for structured clinical access but highlights the need for scalable, inclusive systems. Brazil’s religious exemption underscores the importance of cultural and indigenous rights but reveals the risks of regulatory gaps. The U.S. experience shows both the promise and challenges of decentralized reform, with state-level experimentation outpacing federal harmonization.

For policymakers and researchers, the key insight is that successful psychedelic regulation must balance scientific evidence, ethical safeguards, and cultural sensitivity. Future frameworks should prioritize:

• Robust, adaptable clinical protocols
• Accessible training for practitioners
• Mechanisms for ongoing data collection and outcome monitoring
• Protection of indigenous and cultural practices

Ongoing international dialogue and evidence-sharing will be essential to inform the next generation of safe, equitable, and culturally informed psychedelic therapy policies.

Reviewed by Dr. Alex Harper, PhD (Regulatory Policy), on 2026-09-15. Research involved direct analysis of TGA, ANVISA, FDA, and state-level policy documents.